ID: MRFR/HC/8908-CR | January 2021 | Region: Global | 107 pages
Global hERG Screening Market is expected to register a CAGR of 13.85% during the assessment period of 2020 to 2027, to reach USD 3,304.58 Million by 2027. hERG screening has been an important component of cardiac safety-pharmacology from the past many years. hERG was identified as a potassium-selective cardiac ion channel, Kv11.1, which plays an important role during cardiac repolarization.
The increasing novel drug approvals and the growing prevalence of heart diseases are driving the global hERG screening market. However, the high cost of hERG screening products is expected to hamper the growth of this market during the forecast period. Nevertheless, untapped markets are likely to set a lucrative opportunity for the growth of this market in the near future.
hERG screening is primarily used for the drug discovery process. The increasing number of product launches is anticipated to boost the demand for hERG screening in the coming years. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. The increasing number of novel drugs approvals is expected to support the drugs discovery process that helps the hERG screening market to grow.
Global hERG Screening Market is segmented based on Type into ion Channel and Application.
The hERG screening market, on the basis of type, has been segmented into gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels, where this channel transports positively charged atoms of potassium out of the cells and plays a key role in generating & transmitting electrical signals. The mutation in KCNH2 causes cardiac arrhythmia. Similarly, long QT syndrome is caused by mutations in KCNH2, where an estimated 1 in 5,000–10,000 people suffered from long QT syndrome across the globe.
The global hERG screening market is segmented, based on the ion channel, into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage gated ion channel held the largest share of the hERG screening market, whereas ion gated channel is the fastest-growing segment. The major factors attributed to the market growth of this segment are screening of drugs for (Human Ether-a-go-go related gene) hERG in early stages of drug discovery and development, robust growth in the pharmaceutical companies for hERG screening of lead compounds, and challenges in developing products useful for pharmaceutical and biotechnology applications.
The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to hold a considerable market share. Increasing demand for drug modulation ion channel activity for its application in cardiovascular disorders, metabolic disorders, and oncology are boosting the growth of the hERG screening market.
Global hERG Screening Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas market has been segmented into North America and Latin America, with North America further divided into the US and Canada. The European hERG screening market has been segmented into Western Europe and Eastern Europe. The Western Europe hERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The hERG screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa hERG screening market has been divided into the Middle East and Africa.
The Americas held the largest market share of 37.3% of the hERG screening market in 2019. This share can be attributed to technological development and the high prevalence of cardiac disease in the region. In 2017, according to the American College of Cardiology, emergency medical services-assessed out-of-hospital cardiac arrest occurred in an estimated 356,461 Americans. Similarly, increasing novel drug launches will support the growth of the market. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. These factors are likely to boost the growth of the market during forecast period
The Prominent Players in the Global hERG Screening Market are Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed. Some of the key strategies followed by players operating in the Global hERG screening market are FDA approvals, joint ventures, acquisitions, expansions, and collaborations.
Global HERG Screening Market, By Type
Global HERG Screening Market, By Ion Channel
Global HERG Screening Market, By Application
Global HERG Screening Market, By Region
Available Additional Customizations
|Market Size||2027: USD 3,304.58 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Ion Channel, Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.